These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24096632)

  • 1. Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine.
    Carbone A; Bigoloni A; Galli L; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    AIDS; 2013 Oct; 27(16):2661-3. PubMed ID: 24096632
    [No Abstract]   [Full Text] [Related]  

  • 2. Etravirine(Intelence) for HIV infection.
    Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
    Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
    AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
    Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabie A; Cheret A; Lahoulou R; Raffi F; Pugliese P;
    Infect Dis (Lond); 2016; 48(5):392-8. PubMed ID: 26757613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():1. PubMed ID: 20116620
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug interactions. Interactions with TMC114 and TMC125.
    TreatmentUpdate; 2006; 18(3):8-9. PubMed ID: 17211920
    [No Abstract]   [Full Text] [Related]  

  • 8. A rare case of severe myopathy associated with etravirine use.
    Tommasi C; Tempestilli M; Fezza R; Bellagamba R; Nicastri E; D'offizi G; Pucillo LP; Narciso P
    AIDS; 2010 Apr; 24(7):1088-90. PubMed ID: 20386384
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
    Scott C; Grover D; Nelson M
    AIDS; 2008 May; 22(8):989-90. PubMed ID: 18453859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
    Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S;
    Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
    Poveda E; de Mendoza C; Pattery T; González Mdel M; Villacian J; Soriano V
    AIDS; 2008 Nov; 22(17):2395-8. PubMed ID: 18981781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Kiertiburanakul S; Wiboonchutikul S; Sukasem C; Chantratita W; Sungkanuparph S
    J Clin Virol; 2010 Apr; 47(4):330-4. PubMed ID: 20188624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of etravirine.
    Fullerton DS; Watson MJ; Anderson D; Witek J; Martin SC; Mrus JM
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):485-95. PubMed ID: 20950062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.
    Naccarato M; Yoong D; Kovacs C; Gough K
    Antivir Ther; 2012; 17(3):589-92. PubMed ID: 22293514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-resistant genotyping in HIV-1 therapy.
    Spire B; Souville M
    Lancet; 1999 Sep; 354(9184):1121. PubMed ID: 10509524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.